

CV

ECKHARDT S. FERDINANDI, Ph.D.**Address:**

1720 E 7th Ave
 Vancouver, BC
 Canada V5N 1S2

Phone:

Home: 604-215-1775
 Cell: 778-928-1508
 e-mail: esf1720@telus.net

POSITIONS HELD:

2000 - 2007	VP, Preclinical Research (Retired, 30 March 2007)	Theratechnologies Inc. 2310 Alfred-Nobel Blvd. St-Laurent, QC Canada H4S 2A4
1998 - 2000	Director of Preclinical Development	Lorus Therapeutics, Inc. 2 Meridian Road Toronto, ON Canada M9W 4Z7
1989 - 1998	Scientific Director, Metabolism	Charles River Montreal (formerly ClinTrials BioResearch Ltd.) Senneville (Montreal), Quebec, Canada H9X R3R
1987 - 1989	Head, Drug Metabolism Section Preclinical Development Dept.	Berlex Laboratories, Inc. Cedar Knolls, NJ, USA
1985 - 1987	Senior Research Associate	Wyeth Research
1977 ó 1985	Research Associate	Princeton, NJ, USA
1972 - 1977	Senior Scientist	(and Montreal, QC Canada)
1970 - 1972	NRCC Industrial Postdoctoral Fellow	

EXPERIENCE**THERATECHNOLOGIES:*****Responsibilities***

- Member of the Executive Committee of Theratechnologies managing the preclinical research (Toxicology, Bioanalysis and Immunology) activities related to the development of peptide therapeutics. In that capacity, responsibilities include budget (and human resource) management for internal and outsourced projects as they pertain to the preclinical drug development objectives of the company.
- Participate with senior management on strategic planning related to the research and development focus of the company, and evaluation of external technologies for possible in-licensing and co-development strategies.
- Participate with clinical and regulatory affairs on interactions with regulatory agencies (FDA, TPD, EMEA) related to drug product IND and (currently) NDA submissions.

Specific Accomplishments:

- Built a preclinical development team: total: 10 scientist at PhD, MSc and BSc level, including directors in Toxicology, Bioanalysis and Immunology.
- Implemented in-house laboratory expertise for the following activities: 1. development and qualifications of methods for the bioanalysis of candidate drugs using HPLC, LC-MSMS and immunochemistry techniques; 2. development and qualifications screening of anti-drug antibody screening assays; 3. plasma matrices for potential antibodies raised against exogenous peptides; 3. development and qualifications of cell-based assays for biological potency evaluation (drug formulations) and antibody neutralizing effects.
- Designed and managed the preclinical programs of four candidate peptide therapeutics through various stages of drug development in support of regulatory submissions and clinical trials
 1. TH9507, 44-amino acid hGRF analogue (lead product; indication, HIV-associated lipodystroph), to Phase III (reporting, Dec/06);
 2. TH0318, 30-amino acid GLP-1 analogue (indication, Type 2 diabetes), to Phase I;
 3. TH0396, backup GLP-1 analogue, preclinical pharmacokinetics;
 4. THG213.29, 9-amino acid EP4 receptor antagonist (indication, acute renal failure), to Phase I including large animal pharmacology.
- Managed the development and GMP manufacture of a formulation for parenteral (subcutaneous) injection of a peptide (TH0318) used in a Phase I clinical trial.
- Worked closely with Regulatory Affairs in the preparation and review of documents submitted to regulatory agencies (US, Canada and Japan): Investigator Brochures; Correspondence on specific regulatory issues; IND submissions.
- Participated at FDA and Health Canada meetings for the approval of the TH9507 Phase III clinical trial.
- Prior to the formation of Celmed Biosciences, a spin-off company from Theratechnologies, managed the preclinical aspects of a cell-purging photodynamic therapy (CPDT) under development by Thera for blood cancer indications (NHL and AML) that also included early preclinical evaluation for the use of the technology of GvHD.

LORUS THERAPEUTICS:

- Managed all aspects of the preclinical program of the company related to the development of candidate oncology drugs (biological response modifier, oligonucleotides and low molecular weight compounds).
- Identified and negotiated with contract research organizations (CROs) and investigators at universities and research institutes (including US National Cancer Institute) for the conduct of specific components of the preclinical development program.
- Participated in a medicinal chemistry/rational drug design program for the discovery of novel oncology therapeutics (small molecules) against specific molecular targets.
- Participated in the preparation of preclinical portions of IND submissions and represent the company at regulatory agencies (HPB and FDA) on preclinical, chemistry (manufacture and bioanalytical) issues.
- Participated in negotiations on compound manufacturing including formulation.
- Reviewed and conducted due diligence evaluations of new technologies identified by Lorus for possible acquisition.

BERLEX, CHARLES RIVER MONTREAL and WYETH:

Scientific

- Preclinical and clinical pharmacokinetics and drug disposition:
 - Disposition/pharmacokinetic studies on a broad range of compounds (low molecular weight volatiles to macromolecules including proteins and oligonucleotides) with radiolabels (^{14}C , ^3H , ^{125}I , ^{35}S) and

CV

without by various routes of administration (oral, intravenous bolus and infusion, inhalation, dermal, subcutaneous, intranasal) in typical animal models (mice, rats, rabbits, dogs, monkeys) and man.

- Compartmental and non-compartmental pharmacokinetic analysis.
- Biliary excretion and enterohepatic circulation (rat); lactal secretion (rat); placental transfer (rat).
- Metabolite profiling (TLC and HPLC), and metabolite isolation and identification utilizing MS, GC/MS and NMR spectroscopy.
- Whole body autoradiography
- *In vitro* biotransformation models.
- Bioanalytical method development
- Synthetic organic chemistry, medicinal chemistry (structure/activity studies) and radiolabeled synthesis.

Management

- Department of up to 20 scientists and technical support staff in the conduct of preclinical ADME studies according to U.S. (EPA and FDA) and international (EU and Japanese) GLP regulations.
- Project management.
- Review and approval of department SOPs, protocols and reports: studies conducted under GLP regulations.
- Department budget accountability: preparation and monitoring.
- Performance evaluations.

Regulatory

- Preparation of NDA summaries of metabolism/pharmacokinetic studies.
- Consultation on preclinical drug disposition/pharmacokinetics study designs and packages to support IND and NDA submissions to the regulatory agencies.

Other

- Member of Clinical Protocol Review Committees (Berlex Laboratories).
- Member of Project Review Committees representing Drug Development Department. (Berlex Laboratories).

EDUCATION:

1964	B.Sc., Honours Chemistry	University of British Columbia, Vancouver, BC, Canada
1969	Ph.D., Synthetic Organic Chemistry	McGill University, Montréal, QC, Canada
1969 - 1970	Department of Chemistry (postdoctoral fellow)	University of Colorado Boulder, Colorado

OTHER ACCOMPLISHMENTS:

Author and co-author on numerous scientific publications in peer reviewed journals, on abstracts (presentations) given at various scientific meetings (FASEB, ASPET, CPT, SOT, ISSX and AACR), and coauthor and contributor to patents stemming from medicinal chemistry and drug metabolism studies at Wyeth. Member of a number of scientific societies (AAPS, ASPET, ISSX and AAAS). Participated actively in the North Jersey Drug Metabolism Discussion group (1984-1989), including a tenure as president (1988).

CITIZEN: Canadian

